BCM
EPZM

Bayesian Capital Management’s Epizyme, Inc EPZM Stock Holding History

Bayesian Capital Management’s Portfolio EPZM Stock Details EPZM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-15,911
Closed -$40K – 968
2021
Q4 		$40K Buy
+15,911
New +$62.5K 0.01% 354
2021
Q2 		– Sell
-14,400
Closed -$125K – 713
2021
Q1 		$125K Buy
+14,400
New +$149K 0.03% 486

Other funds holding EPZM

RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bayesian Capital Management's EPZM Position: Q1 2022 in Review

Bayesian Capital Management sold out of Epizyme, Inc (EPZM) in Q1 2022, closing a stake of 15,911 shares — an estimated $40K sold.

Bayesian Capital Management first reported a position in EPZM in Q1 2021 and held it in 2 quarters. The position peaked at $125K in Q1 2021. 120 funds tracked by Wall St. Rank hold EPZM as of Q1 2022.

  • Bayesian Capital Management reported no remaining Epizyme, Inc position as of Q1 2022 after selling out during the quarter.
  • Bayesian Capital Management sold 15,911 Epizyme, Inc shares in Q1 2022, an estimated $40K.
  • Bayesian Capital Management first reported a position in Epizyme, Inc in Q1 2021 and held it in 2 quarters.
  • Bayesian Capital Management's Epizyme, Inc position peaked at $125K in Q1 2021.
  • 120 funds tracked by Wall St. Rank held Epizyme, Inc as of Q1 2022.

Based on Bayesian Capital Management's 13F filing for Q1 2022, filed 16 May 2022.